OCA
LXRX icon

Octagon Capital Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Octagon Capital Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,923,076
Closed -$2.1M – 42
2023
Q3 		$2.1M Hold
1,923,076
– – 0.32% 35
2023
Q2 		$4.4M Buy
+1,923,076
New +$5.1M 0.61% 29

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Octagon Capital Advisors's LXRX Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 1,923,076 shares — an estimated $2.1M sold.

Octagon Capital Advisors first reported a position in LXRX in Q2 2023 and held it in 2 quarters. The position peaked at $4.4M in Q2 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,923,076 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $2.1M.
  • Octagon Capital Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Lexicon Pharmaceuticals position peaked at $4.4M in Q2 2023.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.